David Ebsworth, CEO of the UK-based proteomics company Oxford GlycoSciences, has kept a frenetic pace since assuming the position in July. Jaunts to the US and Israel in his first month on the job are nothing new for the former head of the worldwide pharmaceutical business group of Bayer. Ebsworth, 48, lived in Germany, the US, and Canada while working his way up the big-pharma food chain.

“In the couple of weeks I’ve been here, I’ve been having a lot of fun,” says Ebsworth.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.